SCHEMBL13321788

SCHEMBL13321788

CC(C)(C)OC(=O)CC(O)(c1ccccc1Cl)c1ccnc(-c2c(F)cccc2F)c1NC(=O)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.34
▸ MITF O75030 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PDK1 Q15118 2/20 0.33
▸ PDK2 Q15119 2/20 0.33
▸ PDK3 Q15120 2/20 0.33
▸ PDK4 Q16654 2/20 0.33
▸ SCN9A Q15858 4/20 0.33
▸ SCN5A Q14524 3/20 0.33
▸ NPY2R P49146 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ANO1 Q5XXA6 1/20 0.32
▸ MET P08581 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321789 0.94 PDK1 (0.34) MAPTPDK1PDK2PDK3PDK4
SCHEMBL13321786 0.91 CCNT1 (0.34) LMNAMITFMAPTHPGDMAPK1
SCHEMBL13321787 0.87 CCNT1 (0.35) MAPTPDK1PDK2PDK3PDK4
SCHEMBL2081557 0.86 CCNT1 (0.34) LMNAMITFMAPTHPGDMAPK1
SCHEMBL2079443 0.86 FPR2 (0.32) MAPTSMN1; SMN2ANO1
SCHEMBL2080175 0.82 DGAT2 (0.39) MEN1KMT2A
SCHEMBL12778358 0.76 POLB (0.38) LMNAHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL13353994 0.76 CNR2 (0.33) LMNAMAPTPDK1PDK2PDK3
SCHEMBL2079067 0.76 ABL1 (0.34) MAPK1
SCHEMBL4070987 0.75 P2RY1 (0.33) LMNAMAPTSMN1; SMN2ANO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334294-B2 4,8-diphenyl-polyazanaphthalene derivatives ALMIRALL, S.A. (ES) 2012-12-18 — — US disclosed
US-8334294-B2 4,8-diphenyl-polyazanaphthalene derivatives ALMIRALL, S.A. (ES) 2012-12-18 — — US disclosed
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-27 — — US disclosed
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-27 — — US disclosed
WO-2008131922-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2008-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES MAPK8, MAPK4, MAP3K8 LMNA 2634/4885MITF 1755/4885MAPT 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback